Abstract miR-34a is a transcriptional target of p53, and implicated in carcinogenesis. We studied the role of miR-34a methylation in a panel of hematological malignancies including acute leukemia (AML, ALL), chronic leukemia (CLL and CML), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). The methylation status of miR-34a promoter was studied in 12 cell lines and 188 diagnostic samples by methylation-specific PCR. miR-34a promoter was unmethylated in normal controls but methylated in 75% lymphoma and 37% myeloma cell lines. Hypomethylating treatment led to re-expression of pri-miR-34a transcript in lymphoma cells with homozygous miR-34a methylation. In primary samples at diagnosis, miR-34a methylation was detected in 4% CLL, 5.5% MM samples, and 18.8% of NHL at diagnosis but none of ALL, AML and CML (p=0.011). In MM patients with paired samples, miR-34a methylation status remained unchanged at progression. Amongst lymphoid malignancies, miR-34a was preferentially methylated in NHL (p=0.018), in particular natural killer/T cell (NK/T cell) lymphoma. In conclusion, amongst hematological malignancies, miR-34a methylation is preferentially hypermethylated in NHL, in particular NK/T cell lymphoma, in a tumor-specific manner, therefore the role of miR-34a in lymphomagenesis warrants further study.
Introduction
DNA methylation involves the addition of a methyl group to the number 5 carbon of the cytosine ring in the CpG dinucleotide, by catalyzing the cytosine into methylcytosine through DNA methyltransferase. 1, 2 Cancer cells are characterized by global DNA hypomethylation but gene-specific hypermethylation of promoter-associated CpG islands of tumor suppressor genes (TSGs), resulting in transcriptional repression, and hence serve as an alternative mechanism of gene inactivation. Based on a pathway-specific approach, multiple TSGs across pathways including cell cycle regulation, JAK/STAT signaling, WNT signaling, and DAP kinase-associated intrinsic tumor suppression have been shown to be inactivated by gene hypermethylation in leukemia, lymphoma and multiple myeloma. [3] [4] [5] [6] [7] [8] [9] [10] [11] MicroRNA (miRNA or miR) is a single-stranded, non-coding RNA molecule of 22-25 nucleotides, which leads to downregulation of target protein expression. 12 miRNAs are involved in carcinogenesis. miRNAs can be either oncogenic (oncomir) when TSGs are targeted, or tumor suppressive (tumor suppressive miRNAs) when oncogenes are targeted. 12 Little is known about the role of hypermethylation of tumor suppressor miRNAs in haemic cancers.
p53 is an important tumor suppressor gene inactivated in the majority of cancers.
However, inactivation of p53 in haemic cancers is relatively uncommon, and present 
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14 Deleted: 14 in only about 10%-20% of cases. 13 On the other hand, miR-34a, localized to 1p36, is a transcriptional target of p53, mediating cellular apoptosis. It was shown to be hypermethylated in breast, colon and lung cancers, and downregulate CDK6
translation by binding on the 3' untranslated region (3' UTR) of the CDK6 mRNA, thereby demonstrating the tumor suppressor role of miR-34a. 14 Therefore, we postulated that while genetic inactivation of p53 is uncommon in hematological malignancies, epigenetic inactivation of miR-34a, a direct transcriptional target of p53, may occur in hematological cancers.
In this study, we aimed to study the role of miR-34a methylation in a wide range of hematological malignancies including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). 
Materials and methods

Patient samples
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated and reverse transcribed using mirVana 
Statistical analysis
Correlation between miR-34a methylation status with type of haemic malignancy was computed by the Chi-square test (or Fisher Exact test). All p-values were two-sided. 
Results
Formatted
Lymphoma cell lines.
The profile of methylation of miR-34a in lymphoma cell lines was shown in Figure 1C . SUP-T1 and KARPAS-299 (ALK+) were homozygously methylated for miR-34a; whereas SU-DHL-1 (ALK+) was hemizygously methylated for miR-34a; and only SUP-M2 (ALK+) was completely unmethylated for miR-34a.
Myeloma cell lines.
The profile of methylation of miR-34a in myeloma cell lines was shown in Figure 1D . KMS-12-PE, OPM-2, and WL-2 were homozygously methylated for miR-34a; whereas LP-1, MOLP-8, NCI-H929, RPMI-8226, and U-266 were completely unmethylated for miR-34a.
Primary samples. miR-34a was hypermethylated in none of CML, ALL and AML in addition to 2 (4%) CLL, 3 (5.5%) MM and 6 (18.8%) NHL samples. (Figure 2) Amongst the lymphoid malignancies, there was significantly more frequent miR-34a methylation in NHL than MM, CLL or ALL (p=0.027). In lymphoma samples, miR-34a was more frequently methylated in NK/T cell (N=4; 44.4%) than B-cell (N=2; 16.7%) or PTCL, NOS (N=0) (p=0.039). (Table 2) In the 12 MM patients with bone marrow samples at both diagnosis and progression including two with miR-34a methylation at diagnosis, the methylation status of miR-34a did not change at disease progression (data not shown).
5-AzadC treatment of KARPAS-299 cells
Untreated KARPAS-299 cells were completely methylated for miR-34a. 
Discussion
Methylation studies require precise identification of gene promoter region and
CpG island for proper MSP primer design. The complete sequence of primary miR-34a transcript has previously been described by other groups using rapid amplification of cDNA ends (RACE), 19, 20 and published to GenBank (accession: EF592573). 19 The promoter region and transcription start site (TSS) of miR-34a is therefore mapped to > 30 kb upstream of mature miR-34a. The promoter activity of which under the control of p53, the transcriptional activator of miR-34a, has been confirmed by luciferase reporter assay. 19 CpG island has been found in the above region. Hence, our MSP primer sets designed for this study were selected according to the above region, where > 30 kb upstream of mature miR-34a, with TSS, p53 binding site, proven promoter activity, and CpG island.
In this study, there are several interesting observations. First, we showed that miR-34a is not methylated in normal blood cells but is hypermethylated in myeloma and lymphoma cell lines, and hence it is tumor-specific and consistent with its tumor suppressor role. 19 By contrast, miRs such as miR-127 and miR-373 are hypermethylated in both normal and tumor cells, which will hence represent tissue-specific but not tumor-specific miR methylation. 21 Moreover, in KARPAS-299 cells, miR-34a hypermethylation was associated with gene silencing, which was reversed by hypomethylating treatment.
Secondly, in primary samples, miR-34a was preferentially methylated in lymphoma samples, in particular, extranodal NK/T cell lymphoma, nasal type.
NK-cell lymphoma is an Epstein-Barr virus-associated, aggressive extranodal lymphoma more frequently encountered in Asia, and Central and South America. NK-cell lymphoma. On the other hand, miR-34a methylation is infrequent in other hematological malignancies, in contrast to solid cancer such as prostatic carcinoma, in which miR-34a methylation was detected in 79% of primary solid cancer samples.
14 Thirdly, p53 is an important independent prognostic factor in CLL, with a much inferior survival in patients with p53 inactivation by either del(17p) or p53 mutation. 24 However, unlike solid cancers, in which p53 inactivation may occur in up to 60% of cases, 25 del(17p) and p53 mutation only occur in ≤10% of CLL patients at diagnosis.
However, other components of the p53-associated tumor suppression pathways have been shown to be inactivated by mutation or hypermethylation. For example, ATM, involved in the ATM-CHK2-P53 pathway, is inactivated by del(11q23) in about 20%
of patients is another adverse prognostic factor for survival. 26 Moreover, death-associated protein kinase (DAPK), involved in the DAPK/p14/HDM2/p53/Apaf-1 apoptosis pathway, has been shown to be frequently hypermethylated in CLL. 27 Furthermore, recently, miR-34b and miR-34c, with similar function to miR-34a, has been shown to be hypermethylated in colon cancer. 28 These will be another interesting target of methylation to study.
In addition to hypermethylated promoter, miR-34a is localized to 1p36, which is frequent for loss of heterozygosity (LOH) in different kinds of cancers. LOH serves as one of the mechanisms for TSG inactivation in fulfilling the Kundson's two-hit hypothesis. 29 Loss of 1p heterozygosity is common in solid cancers such as breast, colon, lung, and neuroblastoma. [30] [31] In hematological cancers, loss of 1p36 heterozygosity and the associated tumor suppressor genes is also common. [32] [33] [34] In particular, high frequency of promoter hypermethylation for p73 or LOH of p73 at 1p36 was found in NHL patients. 34 Hence, miR-34a inactivation might potentially result from promoter hypermethylation together with LOH at 1p36 in the samples, thereby fulfilling the Kundson's two-hit hypothesis for TSG inactivation.
In summary, amongst hematological malignancies, miR-34a is preferentially hypermethylated in NHL, in particular NK-cell lymphoma, in a tumor-specific manner. miR-34a methylation is associated with reversible gene silencing, and the role of miR-34a in lymphomagenesis warrants further study. Table) For mir-34a, two sets of ChIP-PCR primers (supplementary Table) embedded in the promoter-associated CpG island were used, one is 540 bp upstream of miR-34a transcription start site (TSS), and the other overlap the p53 binding site which is downstream of miR-34a TSS. 24 ( Figure 4 ) The PCR products were visualized by 6% polyacrylamide gel electrophoresis and the assays were done in duplicate. 
